Interaction Checker

Interacciones de Naldemedina

Naldemedina (Symproic), antagonista opioide, tiene 118 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 75; moderadas: 41; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 2. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (75)

  • Alvimopánantagonista opioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Aprepitantinhibidor de CYP3A4Grave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Belladona y opioopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Bictegravir, emtricitabina y tenofovir alafenamidaantirretroviralGrave

    Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (etiqueta de Bictegravir, emtricitabina y tenofovir alafenamida, Interacciones medicamentosas)

  • Bosentáninductor de CYP3A4Grave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • BuprenorfinaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Buprenorfina y naloxonaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Butalbital, ácido acetilsalicílico, cafeína y codeínabarbitúricoGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Butalbital, paracetamol, cafeína y codeínabarbitúricoGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • ButorfanolopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • ClobazambenzodiazepinaGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • CodeínaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • DarunavirantirretroviralGrave

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir… (etiqueta de Darunavir, Contraindicaciones)

  • Darunavir y cobicistatantirretroviralGrave

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is… (etiqueta de Darunavir y cobicistat, Contraindicaciones)

  • Deferasiroxsuplemento de hierroGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • DexametasonacorticosteroideGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • EfavirenzantirretroviralGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Efavirenz, lamivudina y tenofovirantirretroviralGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • EluxadolinaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • EslicarbazepinaanticonvulsivoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • EtravirinaantirretroviralGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • FentaniloopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • FosfenitoínaanticonvulsivoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • GriseofulvinaantifúngicoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • HidrocodonaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Hidrocodona e ibuprofenoopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Hidrocodona y clorfenaminaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Hidrocodona y homatropinaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Hidrocodona y paracetamolopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • HidromorfonaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • LenacapavirantirretroviralGrave

    Opioid Antagonist: naloxegol ↑ naloxegol Avoid use with SUNLENCA; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (etiqueta de Lenacapavir, Interacciones medicamentosas)

  • LevorfanolopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Lorlatinibinductor de CYP3A4Grave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • MetadonaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Metilnaltrexonaantagonista opioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Mitapivatinductor de CYP3A4Grave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Grave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • MorfinaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Nafcilinaantibiótico del grupo de las penicilinasGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • NalbufinaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Nalmefenoantagonista opioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Naloxegolantagonista opioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Naloxonaantagonista opioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Naltrexonaantagonista opioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Naltrexona y bupropiónantagonista opioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • NevirapinaantirretroviralGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralGrave

    …Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin… (etiqueta de Nirmatrelvir y ritonavir, Contraindicaciones)

  • OliceridinaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • OxcarbazepinaanticonvulsivoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • OxicodonaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Oxicodona y paracetamolopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • OximorfonaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Paracetamol y codeínaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Pentazocina y naloxonaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Petidina (meperidina)opioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • PrimidonaanticonvulsivoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Prometazina y codeínaopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • RemifentaniloopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • RifabutinaantibióticoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • RifampicinaantibióticoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • RifapentinaantibióticoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • RitonavirantirretroviralGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Suzetriginainductor de CYP3A4Grave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • TapentadolopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • TopiramatoanticonvulsivoGrave

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • TramadolopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Tramadol y paracetamolopioideGrave

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (etiqueta de Naldemedina, Interacciones medicamentosas)

Interacciones moderadas (41)

  • Abrocitinibinhibidor de JAKModerada

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

  • AmiodaronaantiarrítmicoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • AtazanavirantirretroviralModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Captoprilinhibidor de la ECAModerada

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

  • CiclosporinainmunosupresorModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Moderada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Dextrometorfano y quinidinafármaco serotoninérgicoModerada

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • DronedaronaantiarrítmicoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Eritromicinaantibiótico macrólidoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • EverolimusinmunosupresorModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Flibanserinadepresor del SNCModerada

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Fluconazolantifúngico azólicoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • FosamprenavirantirretroviralModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Fosaprepitantinhibidor de CYP3A4Moderada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Imatinibinhibidor de CYP3A4Moderada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • IsoniazidaantibióticoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Itraconazolantifúngico azólicoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Ivacaftorinhibidor de CYP3A4Moderada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Ketoconazolantifúngico azólicoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Lapatinibinhibidor de la glicoproteína PModerada

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Ledipasvir y sofosbuvirantiviralModerada

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Lofexidinaagonista alfa-adrenérgicoModerada

    Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (etiqueta de Lofexidina, Interacciones medicamentosas)

  • Mifepristonainhibidor de CYP3A4Moderada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • NefazodonaantidepresivoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Nilotinibfármaco que prolonga el intervalo QTModerada

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Moderada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • PerampanelanticonvulsivoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Posaconazolantifúngico azólicoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • PropafenonaantiarrítmicoModerada

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

  • QuinidinaantiarrítmicoModerada

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Sofosbuvir y velpatasvirantiviralModerada

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Suvorexantsedante-hipnóticoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Ticagrelorantiagregante plaquetarioModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • Voriconazolantifúngico azólicoModerada

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (etiqueta de Naldemedina, Interacciones medicamentosas)

  • ZonisamidaanticonvulsivoModerada

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (etiqueta de Naldemedina, Interacciones medicamentosas)

Sin interacción significativa según la etiqueta (2)

  • AcamprosatoSin interacción

    The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (etiqueta de Acamprosato, Interacciones medicamentosas)

  • Emtricitabina y tenofovirantirretroviralSin interacción

    No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (etiqueta de Emtricitabina y tenofovir, Interacciones medicamentosas)

Compruebe Naldemedina frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.